Depemokimab PK/PD in the 52-week randomised double-blind multicentre Phase III SWIFT-1 trial - Vienna 2024

Recent advances in biological treatments for asthma and chronic obstructive pulmonary disease

Chair(s): Manali Mukherjee, Florence Schleich

Session type: Oral presentation

Depemokimab PK/PD in the 52-week randomised double-blind multicentre Phase III SWIFT-1 trial

Ian Douglas Pavord

EVENTS HOME

Previous presentation

Next presentation

Session content

Enhanced in vitro potency of depemokimab for interleukin-5 inhibition versus mepolizumab

David Jackson

Replay

Poster

Abstract

Slides

Reduction in exacerbations with itepekimab in former smokers with chronic obstructive pulmonary disease (COPD) by prior exacerbation frequency

Klaus F. Rabe

Replay

Poster

Abstract

Slides

A phase 2 study of SelK2 on sputum cell counts in COPD

Dave Singh

Replay

Poster

Abstract

Slides

Depemokimab PK/PD in the 52-week randomised double-blind multicentre Phase III SWIFT-1 trial

Ian Douglas Pavord

Replay

Poster

Abstract

Slides

Dupilumab reduces mucus plugging and volume: phase 4 VESTIGE trial

Celeste Michala Porsbjerg

Replay

Poster

Abstract

Slides

Tezepelumab reduces the expression of MUC5AC in patients with asthma

Kristoffer L. Norheim

Replay

Abstract

Slides

32-week data from a multiple ascending-dose study with verekitug, a novel antibody to the human TSLP receptor (TSLPR), in adults with asthma

Aaron Deykin

Replay

Poster

Abstract

Slides

Proof of Mechanism for an inhaled anti-TSLP fragment antibody, AZD8630/AMG104, in a phase 1 study in healthy adults and asthma patients

Ian C. Scott

Replay

Poster

Abstract

Slides

Safety and PK of KN-002 in subjects with moderate to severe asthma using ICS/LABA

Dave Singh

Replay

Poster

Abstract

Slides

Discussion and Q&A

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}